Jasper Therapeutics (JSPR) Competitors $21.18 +0.20 (+0.95%) (As of 11:20 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends JSPR vs. DCGO, AGFS, GRNA, MNTS, CALT, ARQT, ARDX, RCKT, ANIP, and MESOShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include DocGo (DCGO), AgroFresh Solutions (AGFS), GreenLight Biosciences (GRNA), Momentus (MNTS), Calliditas Therapeutics AB (publ) (CALT), Arcutis Biotherapeutics (ARQT), Ardelyx (ARDX), Rocket Pharmaceuticals (RCKT), ANI Pharmaceuticals (ANIP), and Mesoblast (MESO). Jasper Therapeutics vs. DocGo AgroFresh Solutions GreenLight Biosciences Momentus Calliditas Therapeutics AB (publ) Arcutis Biotherapeutics Ardelyx Rocket Pharmaceuticals ANI Pharmaceuticals Mesoblast DocGo (NASDAQ:DCGO) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends. Does the media prefer DCGO or JSPR? In the previous week, Jasper Therapeutics had 3 more articles in the media than DocGo. MarketBeat recorded 4 mentions for Jasper Therapeutics and 1 mentions for DocGo. Jasper Therapeutics' average media sentiment score of 0.13 beat DocGo's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, DCGO or JSPR? DocGo has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDocGo$624.29M0.69$6.86M$0.2815.00Jasper TherapeuticsN/AN/A-$64.46M-$4.74-4.47 Do analysts prefer DCGO or JSPR? DocGo currently has a consensus price target of $6.10, indicating a potential upside of 45.24%. Jasper Therapeutics has a consensus price target of $74.86, indicating a potential upside of 253.43%. Given Jasper Therapeutics' higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than DocGo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Jasper Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer DCGO or JSPR? DocGo received 5 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 88.64% of users gave Jasper Therapeutics an outperform vote while only 74.58% of users gave DocGo an outperform vote. CompanyUnderperformOutperformDocGoOutperform Votes4474.58% Underperform Votes1525.42% Jasper TherapeuticsOutperform Votes3988.64% Underperform Votes511.36% Do institutionals and insiders believe in DCGO or JSPR? 56.4% of DocGo shares are held by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are held by institutional investors. 2.7% of DocGo shares are held by insiders. Comparatively, 2.7% of Jasper Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is DCGO or JSPR more profitable? DocGo has a net margin of 4.35% compared to Jasper Therapeutics' net margin of 0.00%. DocGo's return on equity of 8.90% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets DocGo4.35% 8.90% 5.72% Jasper Therapeutics N/A -67.64%-58.53% Which has more risk and volatility, DCGO or JSPR? DocGo has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500. SummaryDocGo beats Jasper Therapeutics on 8 of the 15 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$317.70M$2.95B$5.08B$8.80BDividend YieldN/A1.91%5.02%4.07%P/E Ratio-4.4717.5291.2813.60Price / SalesN/A280.411,226.2187.40Price / CashN/A169.3839.4536.27Price / Book3.804.366.906.33Net Income-$64.46M-$41.63M$118.83M$225.93M7 Day Performance-4.16%-5.54%-1.92%-0.96%1 Month Performance6.43%-7.28%-3.75%1.06%1 Year Performance230.42%25.27%31.37%26.59% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics2.6633 of 5 stars$21.18+1.0%$74.86+253.4%+227.3%$317.70MN/A-4.4720DCGODocGo1.6848 of 5 stars$4.20+2.4%$6.10+45.2%-28.9%$428.61M$624.29M14.644,164AGFSAgroFresh SolutionsN/A$3.00flatN/AN/A$161.16M$161.94M-3.19300GRNAGreenLight BiosciencesN/A$0.30flatN/A+0.0%$45.43M$10.20M-0.26280MNTSMomentusN/A$0.55-2.4%N/A-79.6%$14.07M$3.09M0.00120CALTCalliditas Therapeutics AB (publ)0.2585 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180Positive NewsARQTArcutis Biotherapeutics1.7417 of 5 stars$10.13-0.5%$15.50+53.0%+391.8%$1.19B$59.61M0.00150ARDXArdelyx3.9209 of 5 stars$4.97+1.0%$10.42+109.6%+12.3%$1.18B$124.46M0.00267Short Interest ↑Gap UpRCKTRocket Pharmaceuticals4.4162 of 5 stars$12.89-1.2%$51.00+295.7%-40.8%$1.18BN/A-4.74240Analyst ForecastAnalyst RevisionANIPANI Pharmaceuticals4.3361 of 5 stars$55.44+0.6%$77.33+39.5%+7.4%$1.17B$486.82M0.00642Positive NewsMESOMesoblast1.3555 of 5 stars$10.09-2.3%$11.50+14.0%+345.3%$1.15B$5.90M0.0080Gap Down Related Companies and Tools Related Companies DocGo Alternatives AgroFresh Solutions Alternatives GreenLight Biosciences Alternatives Momentus Alternatives Calliditas Therapeutics AB (publ) Alternatives Arcutis Biotherapeutics Alternatives Ardelyx Alternatives Rocket Pharmaceuticals Alternatives ANI Pharmaceuticals Alternatives Mesoblast Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:JSPR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JSPR Stock Alerts